Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce A Peterson

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|May 2, 2019
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicityDaniel F Pease, Bruce A Peterson, Scott Gilles, et al.
Leukemia Research|April 2, 2008
Necrotizing leukoencephalopathy following CHOP chemotherapyAnne H Blaes, Karen S Santa-Cruz, Chung K K Lee, et al.
American Journal of Clinical Pathology|September 17, 2008
Rituximab-induced changes in hematolymphoid tissues found at autopsyAdina M Cioc, Steven M Vanderwerf, Bruce A Peterson, et al.
Leukemia & Lymphoma|December 15, 2016
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)Vicki A Morrison, Edie A Weller, Thomas M Habermann, et al.
Cancer|November 23, 2006
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trialDavid B Duggan, Gina R Petroni, Jeffrey L Johnson, et al.
British Journal of Haematology|August 26, 2010
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI)Ranjana H Advani, Haiyan Chen, Thomas M Habermann, et al.
Pediatric Blood & Cancer|March 30, 2012
Pilot study of vascular health in survivors of Hodgkin lymphomaDaniel A Mulrooney, Kirsten K Ness, Anna Solovey, et al.
Diseases of the Colon and Rectum|March 15, 2019
Colorectal Lymphoma: A Contemporary Case SeriesSteven J Skube, Elliot G Arsoniadis, Megan L Sulciner, et al.
Vascular Health and Risk Management|September 22, 2018
Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot studyAnne H Blaes, Daniel A Mulrooney, Rachel Isaksson Vogel, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|May 2, 2019
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicityDaniel F Pease, Bruce A Peterson, Scott Gilles, et al.
Leukemia Research|April 2, 2008
Necrotizing leukoencephalopathy following CHOP chemotherapyAnne H Blaes, Karen S Santa-Cruz, Chung K K Lee, et al.
American Journal of Clinical Pathology|September 17, 2008
Rituximab-induced changes in hematolymphoid tissues found at autopsyAdina M Cioc, Steven M Vanderwerf, Bruce A Peterson, et al.
Leukemia & Lymphoma|December 15, 2016
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)Vicki A Morrison, Edie A Weller, Thomas M Habermann, et al.
Cancer|November 23, 2006
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trialDavid B Duggan, Gina R Petroni, Jeffrey L Johnson, et al.
British Journal of Haematology|August 26, 2010
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI)Ranjana H Advani, Haiyan Chen, Thomas M Habermann, et al.
Pediatric Blood & Cancer|March 30, 2012
Pilot study of vascular health in survivors of Hodgkin lymphomaDaniel A Mulrooney, Kirsten K Ness, Anna Solovey, et al.
Diseases of the Colon and Rectum|March 15, 2019
Colorectal Lymphoma: A Contemporary Case SeriesSteven J Skube, Elliot G Arsoniadis, Megan L Sulciner, et al.
Vascular Health and Risk Management|September 22, 2018
Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot studyAnne H Blaes, Daniel A Mulrooney, Rachel Isaksson Vogel, et al.
Pageof 3